Loading organizations...
§ Private Profile · 7171 Frederick-Banting St. Montreal, QC H4S 1Z9 Canada
TechBio company developing antibody therapeutics using AI for immuno-oncology, solid tumors, and autoimmune diseases.
Based in Montreal, Quebec, Ability Biologics is a biotechnology company that develops next-generation antibody therapeutics using an artificial intelligence discovery platform. The firm utilizes its proprietary generative AI system, which analyzes massive biological datasets of antibody-antigen interactions, to design highly specific, logic-gated antibodies. These biologics target immune pathways for immuno-oncology, solid tumors, and autoimmune diseases by enabling contextual binding based on microenvironments such as pH or metabolites. The company is currently advancing an internal preclinical pipeline consisting of four therapeutic candidates while pursuing co-development partnerships with larger pharmaceutical firms. Ability Biologics has raised $18 million in total seed funding from a syndicate of institutional investors that includes Amplitude Ventures, Fonds de solidarité FTQ, and Charles River Laboratories. The enterprise was founded in 2023 by Giles Day, Jean-Philippe Bürckert, Huan Besche, Jean-François Gauvin, and Jean-Philippe Therrien.
Ability biologics has raised $30.0M across 2 funding rounds.
Ability biologics has raised $30.0M in total across 2 funding rounds.
Ability biologics has raised $30.0M in total across 2 funding rounds.
Ability biologics's investors include Amplitude Ventures, BDC Venture Capital.
Ability biologics has raised $30.0M across 2 funding rounds. Most recently, it raised $18.0M Seed in June 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2024 | $18M Seed | Amplitude Ventures | BDC Venture Capital | Announced |
| Dec 6, 2023 | $12M Seed | Amplitude Ventures | — | Announced |
Ability Biologics (also referred to as Ability Biotherapeutics) is a Montreal-based biotechnology company developing innovative, targeted immune-modulating biotherapeutics for cancer and autoimmune diseases.[1][2][3] It builds logic-gated antibodies using its proprietary AbiLeap™ platform, which integrates generative AI with a vast antibody-antigen database to create fully human, IgG-based antibodies that activate conditionally in specific microenvironments, offering superior selectivity, reduced toxicity, and broader therapeutic windows.[1][2][3][4] The company serves patients with unmet needs in immuno-oncology, solid tumors, and autoimmune disorders, addressing challenges like off-target effects in current therapies through four preclinical candidates, including pH-activated CD3 bispecific T-cell engagers and novel depletion strategies.[1][3][5] Emerging from stealth in late 2023 with $12 million in seed funding, Ability shows strong growth momentum, including a partnership with Mila (Quebec AI Institute) and plans to expand labs, triple staff by 2028, and advance to human proof-of-concept trials.[2][4][5]
Ability Biologics launched from stealth in December 2023, backed by Amplitude Ventures and co-founded by Giles Day (CEO) and Jean-Philippe Bürckert (VP of Technology), who assembled a team with deep expertise in immunology, antibody engineering, and drug development from bench to clinic.[2][4] The idea emerged from recognizing limitations in existing antibodies—lacking contextual precision—and leveraging AI to engineer "logic-enabled" versions that respond to disease-specific signals.[2][3] Early traction included closing a $12 million seed round to fuel preclinical work and unveiling the AbiLeap™ platform, built on over five years of curated antibody data.[2][4] Pivotal moments include a 2024 partnership with Mila for AI advancements and securing lab space at Inspire Bio Innovations in Montreal, positioning it for preclinical completion and clinical trials by 2026-2028.[4][5]
Ability rides the convergence of AI in drug discovery and precision immuno-oncology, where generative AI accelerates antibody design amid rising demand for safer immunotherapies post-checkpoint inhibitors.[2][4] Timing is ideal: AI-biotech funding rebounds, Quebec's life sciences hub (e.g., Inspire Bio) fosters collaboration, and unmet needs persist in solid tumors and autoimmunity despite market growth to $200B+ by 2030.[5] Favorable forces include vast proprietary data advantages over competitors and regulatory push for targeted therapies reducing side effects.[1][3] Ability influences the ecosystem by pioneering "contextually-gated" antibodies, potentially setting standards for AI-powered biotherapeutics and enabling partnerships for co-development.[2][4]
Ability is poised to advance its four candidates to IND-enabling studies and human trials within 2-3 years, leveraging lab expansions and AI partnerships to scale production and employee headcount threefold by 2028.[1][5] Trends like multimodal AI antibodies and microenvironment-responsive drugs will propel it, amid a biotech resurgence favoring platform companies with clinical traction. Its influence may evolve from preclinical innovator to a leader in selective immunotherapies, partnering with big pharma for global reach—transforming targeted treatments from promising to paradigm-shifting, much like its opening promise of "unparalleled specificity."[2][4]